Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals faces a class‑action lawsuit that could reshape investor confidence and market perception of its biotech innovations and stock volatility.

Inovio Pharmaceuticals’ DNA‑vaccine focus faces a financial slump: stock down, negative earnings, but a $6.82 billion market awaits. Will strategic change lift the biotech?

Inovio Pharmaceuticals faces a stark contrast between its biotech breakthroughs and troubling finances—negative P/E and P/B ratios, volatile shares, and a $147M market cap raise questions about value and future prospects.

Inovio Pharmaceuticals pioneers DNA vaccines for cancer and infectious diseases, navigating biotech hurdles while seeking long‑term impact on global health.

Inovio Pharmaceuticals faces steep financial hurdles amid biotech innovation. Explore why its stock has fallen, its negative earnings, and potential recovery strategies.

Inovio Pharmaceuticals plans a public offering to fund its DNA‑vaccine pipeline, especially INO‑3107, after a Q3 loss that missed estimates.

Inovio Pharmaceuticals is at a critical juncture as it prepares to unveil its quarterly financial results, with analysts predicting a potential turning point in the company’s financial fortunes.

Inovio Pharmaceuticals Inc has recently held its 72nd Annual General Meeting, passing all resolutions with a majority vote, but faces financial challenges and stock volatility.

Inovio Pharmaceuticals Inc. has announced a $25 million public offering to bolster its financial position and advance its pipeline of innovative DNA medicines and vaccines.

Inovio Pharmaceuticals Inc is navigating challenges in the biotech industry, but remains committed to innovation and addressing unmet medical needs through its cutting-edge research and development.